Nektar Therapeutics’ (NKTR) stock jumped over 10% after Piper Sandler initiated coverage with an Overweight rating and a $7 price target, citing the potential of Rezpeg, the company’s lead asset, in treating Alopecia areata (AA). The analyst believes Rezpeg’s unique mechanism of action, targeting Treg cells, could offer a long-term solution for AA patients, potentially transforming their quality of life.
Sun Pharmaceutical Industries Limited (Sun Pharma) announced new data showcasing the efficacy and safety of its dermatology portfolio at the 33rd European Academy of Dermatology and Venereology (EADV) Congress in Amsterdam. Notably, LEQSELVI (deuruxolitinib) demonstrated improved hair satisfaction and significant improvement in depression and anxiety for patients with severe alopecia areata. Additional data presented positive results for ILUMYA (tildrakizumab) in moderate-to-severe plaque psoriasis.
